News | November 07, 2025
Novo Nordisk’s new CEO doubles down on obesity, diabetes push despite mixed Q3
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
The integration of AHG’s specialized cold chain transportation and third-party logistics (3PL) solutions will significantly strengthen UPS Healthcare’s service offerings
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Subscribe To Our Newsletter & Stay Updated
